Medical Marijuana (MJNA) Secures Alzheimer’s Approval in Brazil


Ryan Allway

February 8th, 2017

News, Top News


Medical Marijuana Inc. (OTC Pink: MJNA) has made tremendous progress in realizing its mission of enabling patients everywhere to access high-quality cannabidiol (“CBD”) hemp oil. Recently, the company announced that Brazil’s National Health Surveillance Agency – ANVISA – has granted the filling of a prescription for its Real Scientific Hemp Oil (“RSHO”) to treat a patient suffering from Alzheimer’s disease – another step in the right direction.

In this article, we will look at the company’s expanding reach and the potential opportunity for its products to help those suffering from Alzheimer’s disease.

RSHO’s Expanding Reach

Medical Marijuana Inc.’s Real Scientific Hemp Oil (“RSHO”) products have become the leading cannabidiol (“CBD”) hemp oil product across a growing number of international markets.

In a recent interview, CFN Media sat down with CEO Dr. Stuart Titus to discuss the company’s growing international presence and Latin American expansion:

 

RSHO is a full-spectrum CBD oil extracted from hemp plants grown in Northern Europe without the use of herbicides, pesticides, or chemical fertilizers, and the final product is triple lab tested at ISO/IEC 1725:2005 accredited food safety labs. Strict EU regulations ensure that the hemp oil is extremely pure prior to export, while the products pass all federal requirements for importation into the U.S. and are available in over 40 countries around the world.

In Latin America, RSHO became the first approved medical cannabis product in Brazil, Mexico and Paraguay, along with the U.S. territory of Puerto Rico. The company has moved both vertically into new countries and horizontally into new medical conditions. Brazil’s decision to permit the import of RSHO for the treatment of Alzheimer’s disease is just the latest move in a broad expansion of addressable indications across its Latin American end markets.

$13+ Billion Market Opportunity

Alzheimer’s disease affects nearly 44 million people around the world and cost the healthcare system an estimated $605 billion, according to Alzheimer’s Disease International. The consulting firm GlobalData projects that the global market for AD treatments will more than double in value from $4.9 billion in 2013 to an estimated $13.3 billion by 2023, although high profile failures like Eli Lilly & Co.’s (NYSE: LLY) solanezumab leave a gap in the market.

Cannabidiol has shown promise in treating Alzheimer’s disease in a growing number of early-stage studies, according to ProjectCBD. For example, researchers in 2007 inoculated mice with human beta-amyloid peptides – a hallmark of AD – and treated with them with daily CBDs. The study found that the CBD significantly inhibited the expression of beta-amyloids in a dose-dependent manner and reduced overall neuroinflammation.

The Brazilian government’s decision to authorize a doctor’s prescription for hemp-based CBD oil for the treatment of Alzheimer’s disease acknowledges its potential as a treatment. While more research is needed, the non-toxic nature of hemp-based CBD oil means that patients may be able to realize some benefit before pharmaceutical-grade options are developed and approved, which could prove to be a life-saving decision in some cases.

Looking Ahead

Medical Marijuana Inc. (OTC Pink: MJNA) has become a leader in developing and marketing hemp-based CBD oil products around the world. In addition to RSHO, the company maintains a portfolio of businesses with exposure to the cannabis industry, providing investors with a unique opportunity to invest in the space. The company also continues to draw the attention of international media outlets like the International Business Times.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading